Summary
Angiotensin II (AngII) is an octapeptide hormone with a key role in blood pressure regulation. AngII increases blood pressure by stimulating G protein-coupled receptors in vascular smooth muscle. AngII receptors are therefore an important target in patients with high blood pressure. Strategies to lower high blood pressure (hypertension) include the use of drugs that compete for AngII at the angiotensin II Type 1 receptors (ATR) using ATR antagonists (e.g., irbesartan, valsartan, and losartan). This chapter will demonstrate the subtype specificity of ATR binding and we discuss some of the key experiments that are necessary in optimizing some of the parameters for GPCR screening. The latter protocols include saturation binding to determine K d and B max, as well as competition/inhibition experiments to determine the IC50 of binding. For these experiments we have used rat liver membranes which express ATR (type 1a) in relatively abundant amounts. Additionally, rat liver membrane preparations can be easily prepared in “bulk,” frozen away for extended periods (up to 1 year) and used when necessary with no loss of receptor binding activity using the radiolabeled angiotensin II analogue, [125I][Sar1,I le8]AngII.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Smith, R.G. and Sestili, M.A. (1980) Methods for ligand-receptor assays in clinical chemistry. Clin. Chem. 26, 543–550.
Bylund, D.B. and Toews, M.L. (1993) Radioligand binding methods: practical guide and tips. Am. J. Physiol. 265, L421–L429.
Fang, M., Jaffrey, S.R., Sawa, A., Ye, K., Luo, X., and Snyder, S.H. (2000) Dexras1: a G protein specifically coupled to neuronal nitric oxide synthase via CAPON. Neuron 28, 183–193.
Caballero-George, C., Vanderheyden, P.M., Solis, P.N., Pieters, L., Shahat, A.A., Gupta, M.P., Vauquelin, G., and Vlietinck, A.J. (2001) Biological screening of selected medicinal Panamanian plants by radioligand-binding techniques. Phytomedicine 8, 59–70.
Caballero-George, C., Vanderheyden, P.M., Okamoto, Y., Masaki, T., Mbwambo, Z., Apers, S., Gupta, M.P., Pieters, L., Vauquelin, G., and Vlietinck, A. (2004) Evaluation of bioactive saponins and triterpenoidal aglycons for their binding properties on human endothelin ETA and angiotensin AT1 receptors. Phytother. Res. 18, 729–736.
Motulsky, H. and Christopoulos, A. (2003) Fitting models to biological data using linear regression and nonlinear regression. GraphPad (USA) http://www.graphpad.com/prism/Prism.htm.
Shoichet, B.K. (2006) Interpreting steep dose–response curves in early inhibitor discovery. J. Med. Chem. 49, 7274–7277.
Hines, J., Fluharty, S.J., and Sakai, R.R. (1999) The angiotensin AT(1) receptor antagonist irbesartan has near-peptide affinity and potently blocks receptor signaling. Eur. J. Pharmacol. 384, 81–89.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Humana Press, a part of Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Leifert, W.R., Bucco, O., Abeywardena, M.Y., Patten, G.S. (2009). Radioligand Binding Assays: Application of [125I]Angiotensin II Receptor Binding. In: Leifert, W. (eds) G Protein-Coupled Receptors in Drug Discovery. Methods in Molecular Biology, vol 552. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-60327-317-6_9
Download citation
DOI: https://doi.org/10.1007/978-1-60327-317-6_9
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-60327-316-9
Online ISBN: 978-1-60327-317-6
eBook Packages: Springer Protocols